Sarah joined HERC in September 2018 to complete her DPhil under the supervision of Sarah Wordsworth. She is developing a genetic and environmental risk model for colorectal cancer, and evaluating the clinical utility and cost effectiveness of using this model to stratify approaches to bowel cancer screening in the English Bowel Cancer Screening Programme by prior risk. She is using UK Biobank (genetic, epidemiological and hospital data) to develop her risk model, and a HERC model of bowel cancer screening (Murphy et al. 2017) to evaluate its impact.
Sarah graduated with BMBCh from the University of Oxford. She then undertook an Academic Foundation post at Kings College Hospital, London, followed by an Academic Clinical Fellowship in Medical Oncology in Oxford, researching inherited predisposition to colorectal cancer under the supervision of Professor Ian Tomlinson (now at the University of Birmingham). She subsequently worked as a Medical Oncology registrar before beginning her DPhil studies.
Development and Assessment of a Genetic and Environmental Risk Model for Colorectal Cancer
Dr Sarah Wordsworth (HERC, Nuffield Department of Population Health)
Dr James East (Experimental Medicine, Nufield Department of Medicine)
Professor Julia Hippisley-Cox (Nuffield Department of Primary Care Health Sciences)
Professor Ian Tomlinson (University of Birmingham)
Cancer and climate change: the environmental impact of cancer care.
Briggs S. et al, (2021), Lancet Oncol, 22
COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study.
Lee LYW. et al, (2020), Lancet Oncol, 21, 1309 - 1316
Evaluating the Integration of Genomics into Cancer Screening Programmes: Challenges and Opportunities
Briggs S. and Slade I., (2019), Current Genetic Medicine Reports, 7, 63 - 74
Association analyses identify 31 new risk loci for colorectal cancer susceptibility.
Law PJ. et al, (2019), Nat Commun, 10
Pattern recognition receptor polymorphisms as predictors of oxaliplatin benefit in colorectal cancer
CHURCH DN. et al, (2018), JNCI: Journal of the National Cancer Institute